Turnstone Biologics Corp. Common Stock
Compare this stock
TSBX Stock Report Card
$
32%
Performance
Score:
10/100
TSBX returned -73.77% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
Earnings
Score:
41/100
TSBX has missed earnings 2 times in the last 20 quarters.
Volatility
Score:
44/100
TSBX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Turnstone Biologics Corp. Common Stock Summary
Nasdaq / TSBX
Healthcare
Biotechnology
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
TSBX scored poorly on our reportcard. Here are some similar companies and how they performed.
